Stocks and Investing
Stocks and Investing
Wed, May 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, May 16, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jonathan Wolleben Reiterated (SPRB) at Buy and Held Target at $7 on, May 16th, 2023
Jonathan Wolleben of JMP Securities, Reiterated "Spruce Biosciences, Inc." (SPRB) at Buy and Held Target at $7 on, May 16th, 2023.
Jonathan has made no other calls on SPRB in the last 4 months.
There is 1 other peer that has a rating on SPRB. Out of the 1 peers that are also analyzing SPRB, 0 agree with Jonathan's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jonathan
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $10 on, Thursday, March 23rd, 2023
Contributing Sources